Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study - Takeaways - MDSpire
From the Journals

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

  • By

  • Caroline Helwick

  • May 6, 2026

  • 11 min

Share

  • 1

    The CLIMATE study enrolled 200 patients with stage I testicular cancer.

  • 2

    miR-371a-3p was assessed for its role as a biomarker of minimal residual disease.

  • 3

    Plasma miR-371 outperformed serum in predictive value for recurrence.

  • 4

    Median follow-up period was 18.9 months.

  • 5

    Key findings yielded a hazard ratio of 10.3 for a positive miR-371 result.

  • 6

    Overall recurrence-free survival was 89% for negative results compared to 32% for positive.

  • 7

    Further validation of the miR-371 test is ongoing in various cohorts.

Original Source(s)

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

  • by Caroline Helwick

  • May 6, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...

Experimental Daraxonrasib Shows Promise in Advanced Pancreatic Cancer

Metastatic pancreatic ductal adenocarcinoma remains one of the most challenging malignancies to treat in clinical oncology.

  • by

  • May 6, 2026

  • 5 min